- ►ascopubs.org TE Witzig, IW Flinn, LI Gordon, C … - Journal of Clinical …, 2002 - jco.ascopubs.org PATIENTS AND METHODS: Eligible patients were refractory to rituximab; this was defined as no
objective response to rituximab (375 mg/m 2 weekly for 4 weeks) or time to progression (TTP) of 6
months. The ibritumomab tiuxetan ... Cited by 364 - Related articles - BL Direct - All 6 versions
CA Felix - BBA-Gene Structure and Expression, 1998 - Elsevier The major established cause of acute myeloid leukemia (AML) in the young is cancer chemotherapy.
There are two forms of treatment-related AML (t-AML). Each form has a de novo counterpart.
Alkylating agents cause t-AML ... Cited by 239 - Related articles - All 6 versions
- ►hematologylibrary.org GA Wiseman, LI Gordon, PS Multani, TE … - …, 2002 - bloodjournal.hematologylibrary.org Myelosuppression, including its associated complications such as bleeding, infection, and fatigue,
is the major toxic effect associated with systemic treatment of patients with low-grade non-Hodgkin
lymphoma (NHL). 1 Mild ... Cited by 193 - Related articles - BL Direct - All 4 versions
- ►ascopubs.org TE Witzig, CA White, LI Gordon, GA Wiseman, … - Journal of Clinical …, 2003 - jco.ascopubs.org Purpose: Radioimmunotherapy (RIT) with yttrium-90 ( 90 Y)-labeled anti-CD20 antibody ( 90 Y
ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a high rate of
tumor response in patients with ... Cited by 192 - Related articles - BL Direct - All 7 versions
- ►ascopubs.org MA Smith, L Rubinstein, JR Anderson, D … - Journal of Clinical …, 1999 - jco.ascopubs.org METHODS: Twelve NCI-supported cooperative group clinical trials were identified that use
epipodophyllotoxins at low (< 1.5 g/m 2 etoposide), moderate (1.5 to 2.99 g/m 2 etoposide), or
higher ( 3.0 g/m 2 etoposide) ... Cited by 170 - Related articles - BL Direct - All 7 versions
- ►ascopubs.org INM Micallef, DM Lillington, J Apostolidis, JAL … - Journal of Clinical …, 2000 - jco.ascopubs.org Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook Add
to Reddit Add to Technorati Add to Twitter What's this? ... From the Imperial Cancer Research Fund
Medical Oncology Unit, Departments ... Cited by 148 - Related articles - BL Direct - All 7 versions
MJ Thirman, RA Larson - Hematology/oncology clinics of North America, 1996 - Elsevier Therapy-related leukemia is a neoplastic hematopoietic disorder arising in most cases from a
multipotent stem cell and in a few cases from a lineage-committed progenitor. The terms
therapy-related myelodysplastic ... Cited by 128 - Related articles - BL Direct - All 3 versions
- ►haematologica.com [PDF] G Leone, L Mele, A Pulsoni, F Equitani, L Pagano - Haematologica, 1999 - haematologica.com Background and Objectives. The term secondary leukemia is usually employed to indicate both forms of
acute myeloid leukemia (AML) evolving from pre- vious myelodysplasia and forms of acute leukemia
developing after exposure to ... Cited by 129 - Related articles - BL Direct - All 16 versions
- ►oxfordjournals.org [PDF] LB Travis, RE Curtis, B Glimelius, E … - JNCI Journal of the …, 1993 - jnci.oxfordjournals.org Affiliations of authors: S. Koren, WR Fleischmann, Jr. (Department of Microbiology), EB Whorton, Jr.
(Division of Biostatistics and Epidemiology), The University of Texas Medical Branch, Galveston,
Tex. Correspondence to: WR ... Cited by 120 - Related articles - BL Direct - All 5 versions
LB Travis, RE Curtis, JD Boice Jr, BF Hankey, … - CA A Cancer Journal … - interscience.wiley.com The risk of second malignancies following non-Hodgkin's lymphoma (NHL) was estimated in 29,153
patients diagnosed with NHL between 1973 and 1987 in one of nine areas participating in the National
Cancer Institute's Surveillance, ... Cited by 119 - Related articles - All 3 versions
